Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04428372 · ClinicalTrials.gov registry record · Phase 2
MAnnitol for Blood Pressure Stability in HemoDialysis (MAP-HD)
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT04428372 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 31 participants.
The verdict
NCT04428372, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This proposal will measure the effects of mannitol administration versus placebo in hypotensive-prone, adult, maintenance hemodialysis patients with respect to changes in patient symptoms and blood pressure stability.
Interventions
- DRUG Mannitol
- DRUG 0.9% saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2021-04-06 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04428372
The ClinicalTrials.gov registry entry for NCT04428372 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mannitol is the first listed.
NCT04428372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04428372 about?
NCT04428372 is a clinical study titled "MAnnitol for Blood Pressure Stability in HemoDialysis (MAP-HD)". This proposal will measure the effects of mannitol administration versus placebo in hypotensive-prone, adult, maintenance hemodialysis patients with respect to changes in patient symptoms and blood pressure stability.
What is the current status of trial NCT04428372?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2021-04-06. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT04428372?
The interventions under investigation include: Mannitol (DRUG), 0.9% saline (DRUG).
Who is sponsoring clinical trial NCT04428372?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.